Ipsen Stock: New Historical Record Set at Wednesday's Opening
On Wednesday, February 18, 2026, Ipsen's stock reached a new all-time high, hitting €156.80 during the session and surpassing the previous record set the day before. The stock is up 0.64% at €156.60 in a context of sustained bullish momentum over several weeks. The recent upgrade of the price target by Deutsche Bank has fueled this trend.
Significant Outperformance Relative to Moving Averages
Ipsen's stock is now substantially above its 50-day and 200-day moving averages, which stand at €130.05 and €116.83 respectively. This significant gap reflects the magnitude of the bullish movement initiated in recent months, with an increase of 12.1% over seven days and nearly 40% over a year. The price has also exceeded the upper Bollinger Band (€153.66), indicating a significant extension relative to its recent trajectory.
The RSI is at 77, in the overbought zone, signaling that buying pressure remains dominant but that the stock is moving significantly away from its technical equilibrium levels. This occurs as the stock has just broken through the resistance identified at €155.60, now converted into a reference point. The major support threshold remains set at €121.00, representing a gap of more than 22% relative to the current price, illustrating the steepness of the recent movement.
Deutsche Bank Raises Price Target Ahead of New Record
On the eve of the new record, Deutsche Bank raised its price target on Ipsen from €155.00 to €170.00, accompanying its revision with a buy recommendation. This new target represents a potential upside of approximately 8.6% relative to the current price of €156.60, positioning the target valuation significantly above the levels reached during the session.
This increase occurs in a context of solid quarterly progress for the stock: the stock has shown a nearly 20% increase over three months. The upward revision by the German institution continues the momentum observed in the pharmaceutical laboratory specialized in oncology and rare diseases. The negative beta of -0.12 further confirms the stock's low correlation with the overall market, an attribute that may explain its autonomous behavior during periods of increased volatility on European indices.
